MNMD · Insider Trading
Mind Medicine (MindMed) Inc. Common Shares
Every open-market purchase and sale reported by MNMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-29 | Robert Barrow | Chief Executive Officer | Sell | −25,791 | −$339.07K |
| 2025-12-29 | Mark Sullivan | Chief Legal Officer | Sell | −11,276 | −$148.24K |
| 2025-12-29 | Daniel Karlin | Chief Medical Officer | Sell | −5,600 | −$73.62K |
| 2025-09-26 | Daniel Karlin | Chief Medical Officer | Sell | −7,704 | −$75.27K |
| 2025-09-26 | Robert Barrow | Chief Executive Officer | Sell | −25,797 | −$252.04K |
| 2025-09-26 | Mark Sullivan | Chief Legal Officer | Sell | −11,278 | −$110.19K |
| 2025-06-26 | Mark Sullivan | Chief Legal Officer | Sell | −11,491 | −$78.14K |
| 2025-06-26 | Robert Barrow | Chief Executive Officer | Sell | −26,491 | −$180.14K |
| 2025-06-26 | Daniel Karlin | Chief Medical Officer | Sell | −7,848 | −$53.37K |
| 2025-06-16 | David W Gryska | Director | A | +75,187 deriv. | — |
| 2025-06-16 | Carol A Vallone | Director | A | +75,187 deriv. | — |
| 2025-06-16 | Roger Crystal | Director | A | +75,187 deriv. | — |
| 2025-06-16 | Andreas Krebs | Director | A | +75,187 deriv. | — |
| 2025-06-16 | Suzanne Louise Bruhn | Director | A | +75,187 deriv. | — |
| 2025-06-02 | Brandi Roberts | Chief Financial Officer | A | +500,000 deriv. | — |
| 2025-03-26 | Daniel Karlin | Chief Medical Officer | Sell | −6,836 | −$46.07K |
| 2025-03-26 | Mark Sullivan | Chief Legal Officer | Sell | −6,576 | −$44.32K |
| 2025-03-26 | Robert Barrow | Chief Executive Officer | Sell | −21,208 | −$142.94K |
| 2025-03-26 | Carrie Liao | Chief Accounting Officer | Sell | −2,347 | −$15.82K |
| 2025-03-18 | Matthew T. Wiley | Chief Commercial Officer | A | +350,000 deriv. | — |
| 2025-03-13 | Carrie Liao | Chief Accounting Officer | A | +50,000 | — |
| 2025-03-13 | Daniel Karlin | Chief Medical Officer | A | +115,000 | — |
| 2025-03-13 | Robert Barrow | Chief Executive Officer | A | +350,000 | — |
| 2025-03-13 | Mark Sullivan | Chief Legal Officer | A | +150,000 | — |
| 2024-12-27 | Robert Barrow | Chief Executive Officer | Sell | −19,106 | −$141.96K |
| 2024-12-27 | Carrie Liao | Chief Accounting Officer | Sell | −2,273 | −$16.89K |
| 2024-12-27 | Dan Karlin | Chief Medical Officer | Sell | −6,643 | −$49.36K |
| 2024-12-27 | Mark Sullivan | Chief Legal Officer | Sell | −4,519 | −$33.58K |
| 2024-12-05 | David W Gryska | Director | Buy | +2,500 | +$17.93K |
| 2024-09-25 | Robert Barrow | Chief Executive Officer | Sell | −19,771 | −$118.23K |
| 2024-09-25 | Mark Sullivan | Chief Legal Officer | Sell | −4,430 | −$26.49K |
| 2024-09-25 | Dan Karlin | Chief Medical Officer | Sell | −6,871 | −$41.09K |
| 2024-09-25 | Carrie Liao | Chief Accounting Officer | Sell | −2,352 | −$14.06K |
| 2024-08-26 | David W Gryska | Director | Buy | +3,500 | +$20.93K |
| 2024-08-22 | Wernli Miri Halperin | Executive President | MIXED | +17,405 | −$16.11K |
| 2024-08-20 | Robert Barrow | Chief Executive Officer | Buy | +1,000 | +$6.21K |
| 2024-06-25 | Mark Sullivan | Chief Legal Officer | Sell | −17,854 | −$128.91K |
| 2024-06-25 | Dan Karlin | Chief Medical Officer | Sell | −6,925 | −$50.00K |
| 2024-06-25 | Robert Barrow | Chief Executive Officer | Sell | −15,659 | −$113.06K |
| 2024-06-12 | Carol A Vallone | Director | A | +16,506 deriv. | — |
| 2024-06-12 | Andreas Krebs | Director | A | +16,506 deriv. | — |
| 2024-06-12 | Roger Crystal | Director | A | +16,506 deriv. | — |
| 2024-06-12 | Suzanne Louise Bruhn | Director | A | +16,506 deriv. | — |
| 2024-06-12 | David W Gryska | Director | A | +16,506 deriv. | — |
| 2024-03-26 | Schond L. Greenway | Chief Financial Officer | F | −5,560 | −$54.38K |
| 2024-03-26 | Dan Karlin | Chief Medical Officer | Sell | −6,578 | −$62.49K |
| 2024-03-26 | Robert Barrow | Chief Executive Officer | Sell | −16,519 | −$156.93K |
| 2024-02-29 | Schond L. Greenway | Chief Financial Officer | A | +150,000 deriv. | — |
| 2024-02-29 | Robert Barrow | Chief Executive Officer | A | +400,000 deriv. | — |
| 2024-02-29 | Mark Sullivan | Chief Legal Officer | A | +125,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Robert Barrow | Chief Executive Officer | 778,477 | $11.68M |
| Daniel Karlin | Chief Medical Officer | 425,025 | $6.38M |
| Mark Sullivan | Chief Legal Officer | 282,576 | $4.24M |
| Carrie Liao | Chief Accounting Officer | 144,923 | $2.17M |
| David W Gryska | Director | 19,851 | $297.76K |
| Suzanne Louise Bruhn | Director | 19,623 | $294.34K |
| Roger Crystal | Director | 19,623 | $294.34K |
| Carol A Vallone | Director | 16,544 | $248.16K |
| Andreas Krebs | Director | 15,107 | $226.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MNMD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.